Generic competitors to [Merck's statin] Zocor [whose patent protection expired on June 23, 2006] are grabbing a big share of new prescriptions for cholesterol-lowering drugs and already putting pressure on Pfizer Inc.'s Lipitor, recent data show.
After copycat versions of Zocor became available during the last week of June, they captured 49% of new prescriptions in the U.S. for the medicine known generically as simvastatin. Despite price cuts taken by Merck & Co. to keep Zocor competitive, the brand-name drug's market share slipped to 51% of new prescriptions during the week that ended June 30, according to data from WoltersKluwerHealth. Patent protection for Zocor in the U.S. ended June 23.
Friday, July 14, 2006
Lexapro patent validated
Forest Laboratories won the latest round in the legal fight to preserve its Lexapro anti-depressant drug patent into 2012 (and the stock market responded today with a 16% increase in the company's stock price). Forest Labs has good reason to be pleased as the Wall Street Journal reports today that